| Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. “Janeen's unique blend of corporate development, strategic execution, and cli. |
businesswire.com |
2025-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates. |
businesswire.com |
2025-05-05 12:30:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout |
Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs. The recent stock pullback presents a buying opportunity, driven by profit-taking and broader market weakness, not negative company updates. |
seekingalpha.com |
2025-04-05 12:14:13 |
Czytaj oryginał (ang.) |
| Insiders Are Loading Up on These 4 Biotech Stocks Now |
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so. |
247wallst.com |
2025-03-11 10:45:13 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer. |
businesswire.com |
2025-01-24 18:01:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data |
Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRACTr and TRACIr platforms differentiate it in immunotherapy by enabling tumor-activated bispecific therapeutics for precise cancer targeting with minimal systemic toxicity. JANX's robust balance sheet, with $658.1 million in liquid assets and no debt. Oppenheimer identified Janux as a top biotech buyout candidate for 2025, citing its innovative platform and promising. |
seekingalpha.com |
2025-01-08 11:00:00 |
Czytaj oryginał (ang.) |
| Best-Performing Stocks Of 2024 |
Best-Performing Stocks Of 2024 |
seekingalpha.com |
2025-01-03 01:46:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of. |
businesswire.com |
2024-12-06 21:43:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the pricing of an underwritten public offering of 5,317,460 shares of its common stock at a public offering price of $63.00 per share and pre-funded warrants to purchas. |
businesswire.com |
2024-12-05 01:12:00 |
Czytaj oryginał (ang.) |
| Why Janux Therapeutics Crushed the Market Today |
News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (JANX 11.65%) stock on Wednesday. The clinical-stage biotech's share price ended the day nearly 12% higher, and this was on a very good day for the exchange with the S&P 500 rising by 0.6%. |
fool.com |
2024-12-04 20:23:00 |
Czytaj oryginał (ang.) |
| JANX Stock Hits Record High on Prostate Cancer Study Data |
An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC. |
zacks.com |
2024-12-04 13:05:51 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Announces Proposed Public Offering |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Proposed Public Offering. |
businesswire.com |
2024-12-03 18:01:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst |
On Monday, Janux Therapeutics, Inc. JANX revealed updated interim clinical data for its JANX007 clinical program. |
benzinga.com |
2024-12-03 12:49:39 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results |
The therapeutics company reports encouraging Phase 1 trial results for a novel cancer treatment. |
barrons.com |
2024-12-03 12:39:00 |
Czytaj oryginał (ang.) |
| Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Announces Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC. |
businesswire.com |
2024-12-02 18:30:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event. |
businesswire.com |
2024-11-25 11:00:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation |
Janux Therapeutics' TRACTr and TRACIr platforms show promise in targeting cancer cells while minimizing off-target effects and improving drug half-life. Lead candidate JANX007 demonstrates strong PSA reduction and favorable safety profile in phase 1 trials for metastatic castration-resistant prostate cancer. JANX007's innovative design addresses limitations of previous T cell engagers, showing potential for reduced toxicities and improved patient outcomes. |
seekingalpha.com |
2024-11-19 03:23:33 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--3Q24 Earnings Release. |
businesswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last? |
Janux Therapeutics (JANX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2024-09-13 11:10:14 |
Czytaj oryginał (ang.) |
| Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates |
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.42 per share a year ago. |
zacks.com |
2024-08-07 22:16:06 |
Czytaj oryginał (ang.) |
| Janux Therapeutics Announces Updates to Board of Directors |
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to its Board of Directors. “Eric and Natasha's vast experience and proven leadership in the biopharmaceutical indus. |
businesswire.com |
2024-07-22 20:01:00 |
Czytaj oryginał (ang.) |
| Take the Money and Run: 3 Overbought Stocks to Sell ASAP |
Generally, the idea of selling securities rankles the public's nerve, yet trimming overbought stocks is just as important a discipline as knowing what to buy. It might be even more important than the latter concept. |
investorplace.com |
2024-04-17 17:12:56 |
Czytaj oryginał (ang.) |
| These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come? |
Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs. |
investorplace.com |
2024-04-16 17:19:09 |
Czytaj oryginał (ang.) |
| Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors |
Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies. |
zacks.com |
2024-04-15 17:55:12 |
Czytaj oryginał (ang.) |
| Janux Therapeutics (JANX) is on the Move, Here's Why the Trend Could be Sustainable |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Janux Therapeutics (JANX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2024-04-12 13:50:18 |
Czytaj oryginał (ang.) |
| Why Janux Therapeutics Stock Is Crushing It This Week |
Janux Therapeutics' stock jumped this week after a report stated the company was exploring a sale. The company hasn't publicly commented on whether it's involved in acquisition discussions. |
fool.com |
2024-04-12 09:40:00 |
Czytaj oryginał (ang.) |